Razaxaban

Drug Profile

Razaxaban

Alternative Names: BMS 561389; DPC 906

Latest Information Update: 26 Sep 2006

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Class Anticoagulants; Antithrombotics; Isoxazoles; Pyrazoles; Small molecules
  • Mechanism of Action Factor Xa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Thrombosis

Most Recent Events

  • 31 Dec 2004 Discontinued - Phase-II for Thrombosis in USA (PO)
  • 16 Dec 2003 Data presented at the 45th Annual Meeting of the American Society of Hematology (ASH-2003) have been added to the adverse events and Thrombosis pharmacodynamics and therapeutic trials sections ,
  • 22 May 2001 Phase-II clinical trials for Thrombosis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top